Literature DB >> 21547099

Systemic cholesterol embolization syndrome in a patient positive for anti-cardiolipin antibody.

Motonobu Nakamura1, Yoshiki Tokura.   

Abstract

Cholesterol embolization syndrome (CES) is caused by a cholesterol crystal embolization from atherosclerotic plaques on the walls of arteries. It often occurs after an invasive vascular procedure. CES exhibits several cutaneous manifestations before systemic symptoms take place. Here, we report a case of CES, positive for an anti-cardiolipin antibody, with a history of cerebral infarction. The existence of anti-phospholipid antibody may be a risk factor for CES after an invasive vascular procedure.

Entities:  

Keywords:  anti-cardiolipin antibody; anti-phospholipid antibody syndrome; systemic cholesterol embolization syndrome

Year:  2010        PMID: 21547099      PMCID: PMC3081675          DOI: 10.4161/derm.2.2.13372

Source DB:  PubMed          Journal:  Dermatoendocrinol        ISSN: 1938-1972


  3 in total

Review 1.  Cholesterol embolization syndrome: cutaneous histopathological features and the variable onset of symptoms in patients with different risk factors.

Authors:  M Pennington; J Yeager; H Skelton; K J Smith
Journal:  Br J Dermatol       Date:  2002-03       Impact factor: 9.302

2.  Systemic cholesterol embolization syndrome associated with myeloperoxidase-anti-neutrophil cytoplasmic antibody.

Authors:  Toshiro Sugimoto; Yoshikata Morita; Yukiyo Yokomaku; Keiji Isshiki; Keizo Kanasaki; Yutaka Eguchi; Daisuke Koya; Atsunori Kashiwagi
Journal:  Intern Med       Date:  2006-05-15       Impact factor: 1.271

Review 3.  Antiphospholipid antibody syndrome.

Authors:  Wendy Lim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.